31 results on '"Voorhees, Peter M."'
Search Results
2. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
- Author
-
Ehsan, Hamid, Robinson, Myra, Voorhees, Peter M., Cassetta, Kristen, Borden, Shanice, Atrash, Shebli, Bhutani, Manisha, Varga, Cindy, Pineda-Roman, Mauricio, Friend, Reed, and Paul, Barry A.
- Subjects
- *
MULTIPLE myeloma , *TUMOR suppressor proteins , *STEM cell transplantation , *NUCLEAR proteins , *CANCER cells , *ONCOGENES - Abstract
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which increases nuclear retention of tumor suppressor proteins (TSPs), including p53, thereby limiting the translation of oncogenes, triggering cell cycle arrest and the death of malignant cells. Multiple Myeloma (MM) patients with del17p are deficient in TP53 and have a particularly poor prognosis. Given its unique mechanism of action, we investigated whether Seli has increased efficacy in RRMM patients with del17p compared to other high-risk cytogenetics (OHRC). This is an IRB-approved observational study of RRMM patients with high-risk cytogenetics (del17p, t (4;14), t (14;16) or gain 1q) or standard-risk cytogenetics treated at the Levine Cancer Institute (LCI) with a Seli-based regimen between January 2019 and December 2022. Time-to-event endpoints (PFS, OS) were evaluated using Kaplan–Meier (KM) methods. Log-rank tests compared time-to-event endpoints between cohorts [del17p vs. OHRC vs. standard risk]. We identified 40 RRMM patients with high-risk cytogenetics, including 16 patients with del17p and 24 patients with OHRC, as well as 20 with standard-risk cytogenetics. The median age was 62.5 vs. 69 vs. 65.5 years (del17p group vs. OHRC vs. standard risk). The median prior line of therapies was five (range: 3–16) with similar rates of prior autologous stem cell transplant in all arms (68.8% vs. 62.5% vs. 70.0%). The most frequently used regimens were Seli–Pomalidomide–dexamethasone(dex) or Seli–Carfilzomib–dex (Seli-Kd) in the del17p group and Seli-Kd in the OHRC and standard-risk groups. The median time to start the Seli-based regimen after initial MM diagnosis was 5.6 years for the del17p group, 4.1 years in OHRC, and 4.8 years in the standard-risk group. The median follow-up time after the start of the Seli-based regimen was 10.5 months (mos) in the del17p group, 8.4 mos in OHRC, and 10.3 mos in the standard-risk group. In the del17p group, 50% had an objective response, 41.7% in the OHRC, and 35% in the standard-risk group (p = 0.71). Depth of response was also similar across the arms (12.5% vs. 12.5% vs. 10.0% VGPR p = 0.99). The median OS was 10.9 mos in the del17p group, 10.3 mos in the OHRC, and 10.3 mos in the standard-risk group (p = 0.92). The median OS was 15.5 mos for patients who received Seli as a bridging therapy versus 9 mos for Seli use for other reasons rather than as a bridge. Overall, Seli-based regimens showed promising responses even in this heavily pretreated population. Our analysis suggests that Seli-based regimens lead to similar outcomes among RRMM patients with del17p, OHRC, and standard-risk cytogenetics. This contrasts with previously reported outcomes using combinations of novel therapies in this population, where the del17p patients often have a poorer prognosis. Interestingly, our data suggest that Seli is a particularly effective bridging modality for patients preparing for CAR-T cell therapies in our population. Further investigation into this population is warranted, including in earlier lines of therapy, in hopes of seeing a more durable response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
- Author
-
Voorhees, Peter M., Orlowski, Robert Z., Mulkey, Flora, Watson, Peter, Geyer, Susan, Sanford, Ben L., Bennett, Elizabeth, Chanan‐Khan, Asher A., Bloomfield, Clara D., and Larson, Richard A.
- Subjects
- *
MULTIPLE myeloma treatment , *DOXORUBICIN , *BORTEZOMIB , *LIPOSOMES , *HEMATOLOGY - Abstract
Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (Peg LD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
- Author
-
Voorhees, Peter M., Manges, Robert F., Sonneveld, Pieter, Jagannath, Sundar, Somlo, George, Krishnan, Amrita, Lentzsch, Suzanne, Frank, Richard C., Zweegman, Sonja, Wijermans, Pierre W., Orlowski, Robert Z., Kranenburg, Britte, Hall, Brett, Casneuf, Tineke, Qin, Xiang, Velde, Helgi, Xie, Hong, and Thomas, Sheeba K.
- Subjects
- *
INTERLEUKIN-6 , *MONOCLONAL antibodies , *MULTIPLE myeloma treatment , *ADRENOCORTICAL hormones , *APOPTOSIS , *DRUG efficacy , *DEXAMETHASONE - Abstract
Interleukin-6 ( IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti- IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with relapsed or refractory multiple myeloma who had ≥2 prior lines of therapy, one of which had to be bortezomib-based. Fourteen initial patients received siltuximab alone, 10 of whom had dexamethasone added for suboptimal response; 39 subsequent patients were treated with concurrent siltuximab and dexamethasone. Patients received a median of four prior lines of therapy, 83% were relapsed and refractory, and 70% refractory to their last dexamethasone-containing regimen. Suppression of serum C-reactive protein levels, a surrogate marker of IL6 inhibition, was demonstrated. There were no responses to siltuximab but combination therapy yielded a partial (17%) + minimal (6%) response rate of 23%, with responses seen in dexamethasone-refractory disease. The median time to progression, progression-free survival and overall survival for combination therapy was 4·4, 3·7 and 20·4 months respectively. Haematological toxicity was common but manageable. Infections occurred in 57% of combination-treated patients, including ≥grade 3 infections in 18%. Further study of siltuximab in modern corticosteroid-containing myeloma regimens is warranted, with special attention to infection-related toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis
- Author
-
Uaprasert, Noppacharn, Voorhees, Peter M., Mackman, Nigel, and Key, Nigel S.
- Subjects
- *
THROMBOEMBOLISM , *MULTIPLE myeloma , *IMMUNOREGULATION , *THALIDOMIDE , *CHEMOTHERAPY complications , *PATIENTS - Abstract
Patients with multiple myeloma are at increased risk of venous thromboembolism (VTE) compared to the general population. The introduction of immunomodulatory agents, such as thalidomide and lenalidomide, substantially increases the incidence of VTE in multiple myeloma patients, especially when used in combination with high-dose dexamethasone and/or anthracycline-based chemotherapy. Thromboprophylaxis is recommended for reducing VTE in patients receiving immunomodulatory agent-based regimens. On the other hand, bortezomib, a proteasome inhibitor, is not associated with an increased risk of VTE, as observed by a very low incidence of thrombotic complications in the absence of thromboprophylaxis. Currently, the mechanisms underlying the impact of these agents on VTE are not well-understood. Further studies to investigate the pathogenesis of VTE in multiple myeloma are warranted. These studies may not only yield greater insight into the pathogenesis of disease but may also define novel targets for the prevention and treatment of thromboembolic events in patients with multiple myeloma. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
6. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
- Author
-
Voorhees, Peter M., Chen, Qing, Small, George W., Kuhn, Deborah J., Hunsucker, Sally A., Nemeth, Jeffrey A., and Orlowski, Robert Z.
- Subjects
- *
INTERLEUKIN-6 , *BONE marrow , *CELL death , *MULTIPLE myeloma , *MITOGEN-activated protein kinases , *DEXAMETHASONE - Abstract
Interleukin (IL)-6-mediated signalling attenuates the anti-myeloma activity of glucocorticoids (GCs). We therefore sought to evaluate whether CNTO 328, an anti-IL-6 monoclonal antibody in clinical development, could enhance the apoptotic activity of dexamethasone (dex) in pre-clinical models of myeloma. CNTO 328 potently increased the cytotoxicity of dex in IL-6-dependent and -independent human myeloma cell lines (HMCLs), including a bortezomib-resistant HMCL. Isobologram analysis revealed that the CNTO 328/dex combination was highly synergistic. Addition of bortezomib to CNTO 328/dex further enhanced the cytotoxicity of the combination. Experiments with pharmacologic inhibitors revealed a role for the p44/42 mitogen-activated protein kinase pathway in IL-6-mediated GC resistance. Although CNTO 328 alone induced minimal cell death, it potentiated dex-mediated apoptosis, as evidenced by increased activation of caspases-8, -9 and -3, Annexin-V staining and DNA fragmentation. The ability of CNTO 328 to sensitize HMCLs to dex-mediated apoptosis was preserved in the presence of human bone marrow stromal cells. Importantly, the increased activity of the combination was also seen in plasma cells from patients with GC-resistant myeloma. Taken together, our data provide a strong rationale for the clinical development of the CNTO 328/dex regimen for patients with myeloma. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
7. A case of hook effect in the serum free light chain assay using the Olympus AU400e
- Author
-
McCudden, Christopher R., Voorhees, Peter M., and Hammett-Stabler, Catherine A.
- Subjects
- *
MONOCLONAL gammopathies , *MULTIPLE myeloma , *SERODIAGNOSIS , *HISTORY of medicine , *ANTIGENS , *BLOOD protein electrophoresis - Abstract
Abstract: We describe a case where a woman with an IgGλ monoclonal gammopathy had an undetectable serum free λ light chain due to antigen excess. The patient had a three year history of multiple myeloma and initially presented with an elevated serum free λ light chain. The serum free λ light chain concentration increased over the course of several months to >4000 mg/L (reference interval 5.7–26.3 mg/L) and then suddenly dropped to <3.0 mg/L. Paradoxically, during this time the monoclonal IgGλ concentration measured using serum protein electrophoresis increased from 44 to 59 g/dL. Serial dilution of the patient''s serum specimen revealed that the serum free λ light chain was actually 3130 mg/L. This case represents an example of antigen excess or ‘hook effect’ using the serum free light chain assay. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
8. THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY.
- Author
-
Voorhees, Peter M. and Orlowski, Robert Z.
- Subjects
- *
PROTEINASES , *PROTEINS , *MYELOMA proteins , *CANCER treatment , *PHARMACOLOGY - Abstract
The proteasome, a multicatalytic proteinase complex, is responsible for the majority of intracellular protein degradation. Pharmacologic inhibitors of the proteasome possess in vitro and in vivo antitumor activity, and bortezomib, the first such agent to undergo clinical testing, has significant efficacy against multiple myeloma and non-Hodgkin lymphoma (NHL). Preclinical studies demonstrate that proteasome inhibition potentiates the activity of other cancer therapeutics, in part by downregulating chemoresistance pathways. Early clinical studies of bortezomib-based combinations, showing encouraging activity, support this observation. Molecular characterization of resistance to proteasome inhibitors has revealed novel therapeutic targets for sensitizing malignancies to these agents, such as the heat shock pathway. Below, we review the pharmacologic, preclinical, and clinical data that have paved the way for the use of proteasome inhibitors for cancer therapy; outline strategies aimed at enhancing the efficacy of proteasome inhibitors; and review other potential targets in the ubiquitin proteasome pathway for the treatment of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
9. Follicular Lymphoma With a Burkitt Translocation--Predictor of an Aggressive Clinical Course.
- Author
-
Voorhees, Peter M., Carder, Kathryn A., Smith, Scott V., Ayscue, Lanier H., Rao, Kathleen W., and Dunphy, Cherie H.
- Subjects
- *
DIAGNOSIS , *BURKITT'S lymphoma , *CHROMOSOMAL translocation , *B cell lymphoma , *EPSTEIN-Barr virus diseases - Abstract
Follicular lymphoma is an indolent lymphoma characterized by the (14;18) translocation, which leads to aberrant expression of Bcl-2. Translocations involving 8q24 are most commonly associated with Burkitt lymphoma and result in c-Myc overexpression. We report a case of follicular lymphoma of predominant small cleaved-cell type (grade 1) associated with both a t(14;18)(q32;q21) and a t(8; 22)(q24;q11). The 8q24 translocation predicted an aggressive clinical course, as the lymphoma transformed into acute lymphoblastic leukemia within a year of initial diagnosis. Routine cytogenetic analysis is recommended at initial diagnosis of follicular lymphoma to better identify abnormalities that may predict prognosis and influence therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
10. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
- Author
-
Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya M., Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Voorhees, Peter M., Usmani, Saad Z., and Richardson, Paul G.
- Subjects
- *
BLACK people , *DARATUMUMAB , *LENALIDOMIDE , *BORTEZOMIB , *HEALTH services accessibility - Abstract
Summary: Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant‐eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment‐emergent adverse events. In summary, these findings suggest a benefit of D‐RVd front‐line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
- Author
-
Suvannasankha, Attaya, Bahlis, Nizar, Trudel, Suzanne, Weisel, Katja, Koenecke, Christian, Oriol, Albert, Voorhees, Peter M., Alonso, Aranzazu A., Callander, Natalie S., Mateos, María‐Victoria, Reddy, Nishitha, Hakim, Shawn, LaMacchia, John, Patel, Nashita, Williams, Danaé, Jewell, Roxanne. C., Zhou, Xiangdong, Gupta, Ira, Opalinska, Joanna, and Nooka, Ajay K.
- Abstract
Background Methods Results Conclusions Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell–mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM.DREAMM‐4 (NCT03848845) was an open‐label, single‐arm, phase 1/2 study divided into dose‐escalation (part 1) and dose‐expansion (part 2) phases. Patients were ≥18 years old with ≥3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti‐CD38 agent. Patients received belamaf (2.5 or 3.4 mg/kg, part 1; 2.5 mg/kg, part 2) and 200 mg pembrolizumab for ≤35 cycles.Of 41 enrolled patients, 34 (
n = 6 part 1,n = 28 part 2) who received 2.5 mg/kg belamaf plus pembrolizumab were included in this final analysis. Sixteen patients (47%) achieved an overall response. Minimal residual disease negativity was achieved in three of 10 patients who had very good partial response or better. Five of eight patients who had prior anti–B‐cell maturation antigen therapy achieved partial response or better, including two who had B‐cell maturation antigen–refractory disease. Common grade ≥3 adverse events were keratopathy (38%) and thrombocytopenia (29%). Despite belamaf‐related ocular events, quality‐of‐life measures remained stable over time. No new safety signals were observed.The results of DREAMM‐4 demonstrated clinical activity and a favorable safety profile of belamaf plus pembrolizumab in patients with RRMM. This trial is registered at www.ClinicalTrials.gov as NCT03848845. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
12. Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma.
- Author
-
Atrash, Shebli, Robinson, Myra, Taneja, Alankrita, Paul, Barry, Cassetta, Kristen, Ndiaye, Ami, Varga, Cindy, Block, Jared, Lipford, Edward H., Smith, Elton T., McCall, Chad M., Thurston, Virginia, Foureau, David, Usmani, Saad Z., Voorhees, Peter M., and Bhutani, Manisha
- Subjects
- *
BONE marrow , *MULTIPLE myeloma , *KI-67 antigen , *PROGNOSIS , *PROGRESSION-free survival , *PLASMACYTOMA - Abstract
Background: Ki‐67 is an index of proliferative activity and is an established predictive and prognostic marker in multiple malignancies. However, its prognostic relevance in multiple myeloma (MM) is unclear. We investigated the relationship between Ki‐67 expression and survival outcomes in MM in the era of novel therapies. Methods: We interrogated our database to identify patients with MM, newly diagnosed between July 1, 2013 and December 31, 2020, with Ki‐67 expression assessed by immunohistochemistry (IHC) on bone marrow biopsies. Using an established threshold of 5% we defined Ki‐67low (≤5%) and Ki‐67high (>5%) subgroups for association with progression‐free survival (PFS) and overall survival (OS). Results: Of 167 patients included: 53 (31.7%) had Ki‐67high and 114 had Ki‐67low. More patients with R‐ISS 3 had Ki‐67high (22.2% vs. 9.7%). The gain of 1q21 was overrepresented in the Ki‐67high group (28% vs. 8%). Median PFS in the Ki‐67low group was 3.1 years, and in the Ki‐67high group 1.6 years (log‐rank p <.001, HR: 1.9). Median OS was not reached in the Ki‐67low vs. 4.8 years in the Ki‐67high cohort (HR: 1.9; log‐rank test: p =.018). In the multivariable modeling, after adjusting for other risk factors, HR for Ki‐67high versus Ki‐67low was 2.4 (p <.001) for PFS and 2.1 (p =.026) for OS. Conclusions: Our results demonstrate that a high Ki‐67 index (>5%) is an independent prognostic marker associated with worse OS and PFS in newly diagnosed MM. IHC staining for Ki‐67 on bone marrow biopsies could be easily adopted as a prognostic biomarker for MM in economically constrained healthcare settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.
- Author
-
Voorhees, Peter M., Laubach, Jacob, Anderson, Kenneth C., and Richardson, Paul G.
- Subjects
- *
LETTERS to the editor , *MULTIPLE myeloma , *DEXAMETHASONE , *PATIENTS - Abstract
A letter to the editor is presented in response to the article on peripheral neutropathy in multiple myeloma patients who receive lenalidomide, bortezomib and dexamethasone (RVD) therapy by Jakubowiak and colleages in the 2012 issue.
- Published
- 2013
- Full Text
- View/download PDF
14. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
- Author
-
Sborov, Douglas W., Baljevic, Muhamed, Reeves, Brandi, Laubach, Jacob, Efebera, Yvonne A., Rodriguez, Cesar, Costa, Luciano J., Chari, Ajai, Silbermann, Rebecca, Holstein, Sarah A., Anderson, Larry D., Kaufman, Jonathan L., Shah, Nina, Pei, Huiling, Patel, Sharmila, Cortoos, Annelore, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., and Voorhees, Peter M.
- Subjects
- *
MULTIPLE myeloma , *DARATUMUMAB , *MONOCLONAL gammopathies , *LENALIDOMIDE , *BORTEZOMIB , *STEM cell transplantation - Abstract
Summary: Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) that investigated lenalidomide/bortezomib/dexamethasone (RVd) ± daratumumab (D). Patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplantation (ASCT) received D‐RVd/RVd induction, high‐dose therapy and ASCT, D‐RVd/RVd consolidation and up to 2 years of lenalidomide maintenance therapy ± D. VTE prophylaxis was recommended (at least aspirin, ≥162 mg daily) in accordance with International Myeloma Working Group guidelines. In the safety population (D‐RVd, n = 99; RVd, n = 102), VTEs occurred in 10.1% of D‐RVd patients and 15.7% of RVd patients; grade 2–4 VTEs occurred in 9.1% and 14.7%, respectively. Median time to the first onset of VTE was longer for D‐RVd versus RVd patients (305 days vs 119 days). Anti‐thrombosis prophylaxis use was similar between arms (D‐RVd, 84.8% vs RVd, 83.3%); among patients with VTEs, prophylaxis use at time of first VTE onset was 60.0% for D‐RVd and 68.8% for RVd. In summary, the addition of daratumumab to RVd did not increase the incidence of VTEs, but the cumulative VTE incidence was relatively high in this cohort and anti‐thrombotic prophylaxis use was suboptimal. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.
- Author
-
Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, and Cohen, Adam D.
- Abstract
Background: On the basis of the DREAMM‐2 study (ClinicalTrials.gov identifier NCT03525678), single‐agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received ≥4 prior therapies, including anti‐CD38 therapy. The authors investigated longer term efficacy and safety outcomes in DREAMM‐2 after 13 months of follow‐up among patients who received belamaf 2.5 mg/kg. Methods: DREAMM‐2 is an ongoing, phase 2, open‐label, 2‐arm study investigating belamaf (2.5 or 3.4 mg/kg) in patients with RRMM who had disease progression after ≥3 lines of therapy and were refractory to immunomodulatory drugs and proteasome inhibitors and refractory and/or intolerant to an anti‐CD38 therapy. The primary outcome was the proportion of patients that achieved an overall response, assessed by an independent review committee. Results: As of January 31, 2020, 10% of patients still received belamaf 2.5 mg/kg. Thirty‐one of 97 patients (32%; 97.5% confidence interval [CI], 21.7%‐43.6%) achieved an overall response, and 18 responders achieved a very good partial response or better. Median estimated duration of response, overall survival, and progression‐free survival were 11.0 months (95% CI, 4.2 months to not reached), 13.7 months (95% CI, 9.9 months to not reached), and 2.8 months (95% CI, 1.6‐3.6 months), respectively. Response and survival outcomes in patients who had high‐risk cytogenetics or renal impairment were consistent with outcomes in the overall population. Outcomes were poorer in patients with extramedullary disease. In patients who had a clinical response and prolonged dose delays (>63 days; mainly because of corneal events), 88% maintained or deepened responses during their first prolonged dose delay. Overall, there were no new safety signals during this follow‐up. Conclusions: Extended follow‐up confirms sustained clinical activity without new safety signals with belamaf in this heavily pretreated patient population with RRMM. Extended follow‐up of patients enrolled in the ongoing phase 2 DREAMM‐2 study confirms sustained clinical activity without new safety signals in patients with relapsed or refractory multiple myeloma who receive belantamab mafodotin 2.5 mg/kg every 3 weeks. These data show that belantamab mafodotin has the potential to shift the treatment paradigm in this heavily pretreated, anti‐CD38 monoclonal antibody–exposed patient population, which has a poor prognosis and few alternative treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
- Author
-
Foster, Matthew C., Amin, Chirag, Voorhees, Peter M., van Deventer, Hendrik W., Richards, Kristy L., Ivanova, Anastasia, Whitman, Jennifer, Chiu, Wingkeung Michael, Barr, Nathan D., and Shea, Thomas
- Subjects
- *
ACUTE myeloid leukemia treatment , *DISEASE relapse , *HEPATOTOXICOLOGY , *HEMATOLOGY , *DRUG dosage - Abstract
Clofarabine and gemtuzumab ozogamicin (GO) are active agents against acute myeloid leukemia (AML), but have not previously been tested in combination. We conducted a phase I study to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of clofarabine when combined with GO in adult patients with relapsed or refractory AML. Twenty patients received clofarabine (10, 20 or 30 mg/m2) on days 1-5, with GO 3 mg/m2/day on days 1, 4 and 7. Common dose-limiting toxicities were prolonged myelosuppression and hepatotoxicity. Clofarabine 20 mg/m2 was the MTD, but with a DLT rate of 0.38 (5/13) - a rate that is prohibitively high to recommend for phase II study. The overall response rate (complete response [CR] + complete response with incomplete hematologic recovery [CRi]) was 42% among all patients. Thus, this combination demonstrated activity in relapsed and refractory patients, but further testing of the combination using lower doses of GO may identify more favorable rates of toxicity while maintaining efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
- Author
-
Biehn, Suzanne E., Moore, Dominic T., Voorhees, Peter M., Garcia, Reynaldo A., Lehman, Mary Jo, Claire Dees, E., and Orlowski, Robert Z.
- Subjects
- *
MULTIPLE myeloma , *B cell lymphoma , *DOXORUBICIN , *DRUG therapy , *CLINICAL drug trials , *CLINICAL trials , *C-reactive protein , *TUMOR treatment - Abstract
A phase I study of a combination of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin showed significant anti-tumor activity against advanced multiple myeloma, with 36% of patients achieving a complete or near-complete response and 73% having a partial response or better. Given this encouraging efficacy, it was therefore of interest to update the prior experience and define parameters such as time to progression, time to retreatment, and overall survival. Additional follow-up was collected on all evaluable multiple myeloma patients and revealed a median time to progression of 9.3 months versus 3.8 months on whatever had been the patient’s prior therapy. Time to retreatment was prolonged from 5.9 months after the patient’s prior therapy to 24.2 months after bortezomib with pegylated liposomal doxorubicin. The median overall survival after therapy with bortezomib and pegylated liposomal doxorubicin was 38.3 months. These findings compare favorably with results reported for bortezomib alone and support the possibility that the bortezomib/pegylated liposomal doxorubicin regimen may provide superior efficacy against relapsed/refractory multiple myeloma. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
18. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
- Author
-
Foureau, David, Bhutani, Manisha, Guo, Fei, Rigby, Katherine, Leonidas, Marina, Tjaden, Elise, Fox, Andee, Atrash, Shebli, Paul, Barry, Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *MASS spectrometry , *FLOW cytometry , *MONOCLONAL gammopathies , *MONOCLONAL antibodies , *IMMUNOGLOBULIN producing cells - Abstract
Keywords: mass spectrometry; multiple myeloma; NGF-MRD EN mass spectrometry multiple myeloma NGF-MRD 6933 6936 4 10/21/21 20211015 NES 211015 GLO:FU4O/15oct21:cam44254-toc-0001.jpg PHOTO (COLOR): . gl AKNOWLEDGEMENTS The authors thank Dr. Hazel O'Connor for providing valuable editing suggestions. To our knowledge, this is the first report comparing MALDI-TOF-MS and LC-MS serum M-protein analyses to bone marrow NGF at different sensitivity thresholds. Bone marrow aspirates were prospectively tested using standardized 2-tubes 8-colors NGF methods, and MRD status was established at three levels of sensitivity: 10 SP -4 sp , 10 SP -5 sp , and 10 SP -6 sp .4 Serum eluates were tested retrospectively by MALDI-TOF-MS and Ig-LC-MS for the presence of a serum M-protein using the same I m i / I z i as defined at baseline. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
19. Approaching the first relapse after autologous transplant in multiple myeloma.
- Author
-
Atrash, Shebli, Hamadeh, Issam, Matusz‐Fisher, Ashley, Ndiaye, Ami, Bhutani, Manisha, Voorhees, Peter M., Barry, Paul, and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma treatment , *AUTOGRAFTS , *CANCER relapse - Abstract
Multiple myeloma(MM) is an incurable plasma cell malignancy. Despite an improvement in OS over the past 2 decades, most patients do experience disease relapse. A subset of patients who experience an early disease relapse within 1‐2 years posttransplant, and considered functional high‐risk. Recent findings implicated high‐risk cytogenetic features and minimal residual disease as negative prognostic factors, each independently associated with early relapse among autologous stem cell transplant recipients(ASCT). The spectrum of disease relapse could range from asymptomatic/biochemical to more aggressive forms such as plasma cell leukemia. Hence, it is imperative that therapy be tailored based on these patterns of relapse upon presentation. The past few years have witnessed an explosion in the armamentarium of second‐line agents for the treatment of relapsed MM. Accordingly, choosing the optimal regimen has become quite challenging for the practicing clinician. In this review, we outline the approach for therapy selection, which takes into account underlying comorbid conditions, duration of response, presence of high‐risk features, etc Due to a better understanding of disease biology coupled with the advances in molecular techniques, the treatment landscape of relapsed MM (posttransplant) will most likely continue to evolve. Novel agents with distinct modes of action, such as immune therapies and novel oral agents are undergoing investigation in the relapsed setting. Once approved, these agents could potentially alter the course of the disease and possibly challenge the role of ASCT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Management of newly diagnosed transplant ineligible multiple myeloma.
- Author
-
Atrash, Shebli, Bhutani, Manisha, Paul, Barry, Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *STEM cell transplantation , *INFECTION prevention , *HEMATOLOGIC malignancies , *TRANSPLANTATION of organs, tissues, etc. , *PLASMACYTOMA - Abstract
Multiple myeloma (MM) is a chronically managed blood cancer with a median age of 69 years at the time of diagnosis. Although high dose melphalan and autologous stem cell transplantation (ASCT) remains a standard of care for eligible patients, more than half of the newly diagnosed MM patients are deemed ineligible due to comorbidities or complications of the disease by itself. In this setting, where ASCT is deemed inappropriate, patients could still achieve durable and deep responses if given the appropriate treatment plan. The key concepts of optimizing induction and maintenance strategies while minimizing side-effects are discussed in this review, especially in the context of employing novel agent combinations. It is important to understand the balance between safety and efficacy for each regimen, utilizing maintenance strategy and the best supportive care measures (bone health, infection prevention, and treatment, pain management, etc.). Here, we examine the evidence behind each of those principles and review results from clinical trials for transplant-ineligible (TI) MM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Author
-
Hari, Parameswaran, Paba-Prada, Claudia E., Voorhees, Peter M., Frye, John, Chang, Yu-Lin, Moreau, Philippe, Zonder, Jeffrey, Boccia, Ralph, and Shain, Kenneth H.
- Subjects
- *
MULTIPLE myeloma , *DEXAMETHASONE , *PROTEASOME inhibitors , *CANCER treatment - Abstract
• Efficacy and safety w/ oprozomib-dexamethasone in RRMM patients were investigated. • ORR for the 2/7 schedule was 58.7% overall and 46.4% for bor-refractory patients. • Limitations including GI toxicities and intrapatient PK variability halted study. • New formulation of oprozomib w/ improved gastrointestinal tolerability is warranted. Oprozomib is an oral proteasome inhibitor with activity in multiple myeloma (MM). Our phase 1b/2 study examined the safety and efficacy of oprozomib with dexamethasone in patients with relapsed and refractory MM. Oprozomib was administered with a 5/14 or 2/7 schedule with dexamethasone. Phase 1b primary objectives were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of oprozomib; phase 2 primary objectives were to determine overall response rate (ORR) and safety/tolerability of the RP2D. Between July 2, 2013, and August 29, 2016, data were available on 65 enrolled patients (5/14 schedule, n = 19; 2/7 schedule, n = 46). In phase 1b, MTD was 180 mg (5/14 schedule) and not reached (2/7 schedule); RP2D was 300 mg (2/7 schedule). In phases 1b and 2, ORR across dosing cohorts (210–330 mg) for the 2/7 schedule was 58.7% overall and 46.4% for bortezomib-refractory patients (n = 28). All patients reported ≥1 treatment-emergent adverse event (AE); the most common AEs were gastrointestinal. Grade ≥3 AEs occurred in 78.9% and 82.6% of patients on the 5/14 and 2/7 schedules, respectively. The oprozomib and dexamethasone combination has encouraging activity and could be an important MM therapy if gastrointestinal tolerability is improved. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
- Author
-
Arnall, Justin R., Moore, Donald C., Hill, Hailey L., Griffin, Sarah, Mueller, Maxine K., Lavery, Lesli A., Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
PATIENT compliance , *MULTIPLE myeloma - Abstract
A retrospective chart review of patients at our institution who received split-dose daratumumab between January 2015 and August 2018 was conducted to assess the impact of a split-dose daratumumab protocol on the feasibility of outpatient administration. One patient experienced a grade 3 IRR on day 1 of treatment; the patient then received day 2 daratumumab 8 mg/kg without any recurrence of IRR. Twelve patients (92%) continued daratumumab following split dosing; one patient experienced rapid disease progression that resulted in the patient electing to seek hospice treatment. Patient adherence to the prescribed treatment regimen should continue to be weighed, but for this patient lack of adherence was not overall detrimental to his tolerability to daratumumab. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
23. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
- Author
-
Hussain, M. Junaid, Robinson, Myra M., Hamadeh, Issam, Arnall, Justin, Bhutani, Manisha, Atrash, Shebli, Friend, Reed, Pineda‐Roman, Mauricio, Symanowski, James T., Usmani, Saad Z., and Voorhees, Peter M.
- Subjects
- *
MULTIPLE myeloma , *THALIDOMIDE , *BORTEZOMIB , *T helper cells , *CYTOTOXIC T cells , *KILLER cells - Abstract
The article focuses on the role of Daratumumab, pomalidomide and dexamethasone (Pd) combination therapy for the treatment of relapsed and refractory multiple myeloma. It mentions the addition of daratumumab to the Pd backbone (DaraPd) for the patients with relapsed and refractory multiple myelom and also discussions on daratumumab that depletes levels of CD38 (cluster of differentiation 38).
- Published
- 2019
- Full Text
- View/download PDF
24. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
- Author
-
Bhutani, Manisha, Foureau, David, Zhang, Qing, Robinson, Myra, Wynn, Adina S., Steuerwald, Nury M., Druhan, Lawrence J., Guo, Fei, Rigby, Katherine, Turner, Mitchell, Slaughter, Daniel, Friend, Reed, Atrash, Shebli, Symanowski, James T., Avalos, Belinda R., Copelan, Edward A., Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *KILLER cells , *STEM cell transplantation , *T cells , *BONE marrow , *HEMATOPOIETIC system - Abstract
Highlights • NK, NK-T, and T cell peripheral immunotypes differ between MRDpos and MRDneg MM. • Lenalidomide maintenance has pleiotropic effects on NK, NK-T, and T cell immunotypes. • Peripheral T cells skew to an exhausted state during maintenance in MRDpos patients. Abstract Data indicate reversal of immune dysfunction with active treatment; however, the precise contribution of specific immune effector and immune suppressor components to achieve a minimal residual disease (MRD) state and immunomodulatory drug–mediated immunomodulatory effects in multiple myeloma (MM) patients remains poorly understood. In this prospective proof-of-principle study we sought to determine the dynamic alterations in natural killer (NK), NK-T, and T cells, including maturation and activating/inhibitory repertoire associated with MRDpos versus MRDneg status after autologous stem cell transplantation (ASCT) and during lenalidomide-based maintenance therapy. Of the 46MM patients enrolled, 36 had bone marrow MRD assessment 60+ days post-ASCT, 30 had longitudinal blood immunotyping during maintenance (pretherapy and after cycles 1, 3, and 6), and 20 had both MRD assessment and longitudinal immunotyping. Multicolor flow cytometry was used for MRD and immunotyping. Although the absolute number of NK cells was significantly lower in patients with MRDpos response, phenotypically NK cells in these patients displayed higher expression of activating receptors KIRDS4 and decreased expression of inhibitory molecules NKG2A compared with the MRDneg group. Furthermore, we observed significantly lower frequencies of T cells displaying KIR3DL1 in MRDpos versus MRDneg patients. Longitudinal immunotyping during lenalidomide maintenance showed loss of mature NK effector function, augmentation of NK-T effector function, and acquisition of PD1 independent anergic state. Our findings also suggest skewing of T cells toward an exhausted state during the maintenance phase in MRDpos patients. Put together, these observations provide a distinctive signature for MRDneg and MRDpos groups. These data support exploration of immune profiling in prospective clinical trials according to MRD-defined responses to identify patients that may benefit from maintenance intensification/modification or maintenance withdrawal. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
- Author
-
Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M, Reeves, Brandi, Libby, Edward N, Richardson, Paul G, Anderson, Larry D Jr, Sutherland, Heather J, Yong, Kwee, Hoos, Axel, Gorczyca, Michele M, Lahiri, Soumi, He, Zangdong, Austin, Daren J, Opalinska, Joanna B, and Cohen, Adam D
- Subjects
- *
B cells , *CELL receptors , *COMPARATIVE studies , *DRUG resistance in cancer cells , *IMMUNOGLOBULINS , *RESEARCH methodology , *MEDICAL cooperation , *MULTIPLE myeloma , *RESEARCH , *TIME , *DISEASE relapse , *EVALUATION research , *TREATMENT effectiveness - Abstract
Background: B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis superfamily required for plasma cell survival. BMCA is universally detected on patient-derived myeloma cells and has emerged as a selective antigen to be targeted by novel treatments in multiple myeloma. We assessed the safety, tolerability, and preliminary clinical activity of GSK2857916, a novel anti-BCMA antibody conjugated to microtubule-disrupting agent monomethyl auristatin F, in patients with relapsed and refractory multiple myeloma.Methods: We did an international, multicentre, open-label, first-in-human phase 1 study with dose escalation (part 1) and dose expansion (part 2) phases, at nine centres in the USA, Canada, and the UK. Adults with histologically or cytologically confirmed multiple myeloma, Eastern Cooperative Oncology Group performance status 0 or 1, and progressive disease after stem cell transplantation, alkylators, proteasome inhibitors, and immunomodulators were recruited for this study. In part 1, patients received GSK2857916 (0·03-4·60 mg/kg) through 1 h intravenous infusions once every 3 weeks. In part 2, patients received the selected recommended phase 2 dose of GSK2857916 (3·40 mg/kg) once every 3 weeks. Primary endpoints were maximum tolerated dose and recommended phase 2 dose. Secondary endpoints for part 2 included preliminary anti-cancer clinical activity. All patients who received one or more doses were included in this prespecified administrative interim analysis (data cutoff date June 26, 2017), which was done for internal purposes. This study is registered with ClinicalTrials.gov, number NCT02064387, and is ongoing, but closed for recruitment.Findings: Between July 29, 2014, and Feb 21, 2017, we treated 73 patients: 38 patients in the dose-escalation part 1 and 35 patients in the dose-expansion part 2. There were no dose-limiting toxicities and no maximum tolerated dose was identified in part 1. On the basis of safety and clinical activity, we selected 3·40 mg/kg as the recommended phase 2 dose. Corneal events were common (20 [53%] of 38 patients in part 1 and 22 [63%] of 35 in part 2); most (18 [47%] in part 1 and 19 [54%] in part 2) were grade 1 or 2 and resulted in two treatment discontinuations in part 1 and no discontinuations in part 2. The most common grade 3 or 4 events were thrombocytopenia (13 [34%] of 38 patients in part 1 and 12 [34%] of 35 in part 2) and anaemia (6 [16%] in part 1 and 5 [14%] in part 2). There were 12 treatment-related serious adverse events and no treatment-related deaths. In part 2, 21 (60·0%; 95% CI 42·1-76·1) of 35 patients achieved an overall response.Interpretation: At the identified recommended phase 2 dose, GSK2857916 was well tolerated and had good clinical activity in heavily pretreated patients, thereby indicating that this might be a promising candidate for the treatment of relapsed or refractory multiple myeloma.Funding: GlaxoSmithKline. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
26. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
- Author
-
Yan, Xiaoyu, Clemens, Pamela L., Puchalski, Thomas, Lonial, Sagar, Lokhorst, Henk, Voorhees, Peter M., Usmani, Saad, Richardson, Paul G., Plesner, Torben, Liu, Kevin, Orlowski, Robert Z., Losic, Nedjad, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Ruixo, Juan Jose Perez, Zhou, Honghui, and Xu, Xu Steven
- Subjects
- *
MULTIPLE myeloma treatment , *IMMUNOGLOBULIN G , *DRUG efficacy , *THERAPEUTIC use of monoclonal antibodies , *HEALTH outcome assessment , *MULTIPLE myeloma diagnosis , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *MONOCLONAL antibodies , *EVALUATION research , *MEDICAL cooperation , *DISEASE relapse , *TREATMENT effectiveness , *COMPARATIVE studies , *RESEARCH funding , *MULTIPLE myeloma , *BIOTRANSFORMATION (Metabolism) , *DRUG resistance in cancer cells - Abstract
Objective: The aim of this study was to understand the influence of disease and patient characteristics on exposure to daratumumab, an immunoglobulin Gκ (IgGκ) monoclonal antibody, and clinical outcomes in relapsed or refractory multiple myeloma (MM).Patients and Methods: Baseline myeloma type, albumin levels, renal/hepatic function, age, sex, race, weight, Eastern Cooperative Oncology Group (ECOG) status, refractory status, and number of prior therapies were evaluated using data from two clinical studies-GEN501 (N = 104) and SIRIUS (N = 124).Results: Daratumumab clearance was approximately 110% higher in IgG myeloma patients than non-IgG myeloma patients, leading to significantly lower exposure in IgG myeloma patients based on maximum trough serum concentrations (p < 0.0001). However, the overall response rate was similar for IgG and non-IgG myeloma patients (odds ratio 1.08, 95% confidence interval 0.54-2.17, p = 0.82). For a given exposure, the drug effect was significantly higher (approximately two times) in IgG versus non-IgG patients (p = 0.03). The influence of other patient and disease characteristics on daratumumab exposure was minimal and no significant effect on efficacy was observed (p ≥ 0.1). The incidences of infections and overall grade 3 or higher adverse events in subpopulations were generally consistent with that of the overall population.Conclusion: Due to competition with the MM-produced IgG M-protein for neonatal Fc receptor protection from clearance, IgG-based monoclonal antibodies in general may have significantly higher clearance and lower concentrations in IgG MM patients compared with non-IgG MM patients. Careful evaluation of the impact of exposure and patient and disease characteristics on safety and efficacy is warranted for all IgG-based monoclonal antibodies used in MM. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
- Author
-
Yee, Andrew J, Bensinger, William I, Supko, Jeffrey G, Voorhees, Peter M, Berdeja, Jesus G, Richardson, Paul G, Libby, Edward N, Wallace, Ellen E, Birrer, Nicole E, Burke, Jill N, Tamang, David L, Yang, Min, Jones, Simon S, Wheeler, Catherine A, Markelewicz, Robert J, and Raje, Noopur S
- Subjects
- *
MULTIPLE myeloma treatment , *CANCER relapse , *DEXAMETHASONE , *HISTONE deacetylase inhibitors , *DRUG dosage , *DRUG efficacy , *CANCER , *ANTINEOPLASTIC agents , *CLINICAL trials , *COMPARATIVE studies , *ENZYME inhibitors , *HETEROCYCLIC compounds , *RESEARCH methodology , *MEDICAL cooperation , *MULTIPLE myeloma , *RESEARCH , *THALIDOMIDE , *HYDROXY acids , *EVALUATION research - Abstract
Background: Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. Motivated by findings from preclinical studies showing potent synergistic activity with ricolinostat and lenalidomide, our goal was to assess the safety and preliminary activity of the combination of ricolinostat with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma.Methods: In this multicentre phase 1b trial, we recruited patients aged 18 years or older with previously treated relapsed or refractory multiple myeloma from five cancer centres in the USA. Inclusion criteria included a Karnofsky Performance Status score of at least 70, measureable disease, adequate bone marrow reserve, adequate hepatic function, and a creatinine clearance of at least 50 mL per min. Exclusion criteria included previous exposure to HDAC inhibitors; previous allogeneic stem-cell transplantation; previous autologous stem-cell transplantation within 12 weeks of baseline; active systemic infection; malignancy within the last 5 years; known or suspected HIV, hepatitis B, or hepatitis C infection; a QTc Fridericia of more than 480 ms; and substantial cardiovascular, gastrointestinal, psychiatric, or other medical disorders. We gave escalating doses (from 40-240 mg once daily to 160 mg twice daily) of oral ricolinostat according to a standard 3 + 3 design according to three different regimens on days 1-21 with a conventional 28 day schedule of oral lenalidomide (from 15 mg [in one cohort] to 25 mg [in all other cohorts] once daily) and oral dexamethasone (40 mg weekly). Primary outcomes were dose-limiting toxicities, the maximum tolerated dose of ricolinostat in this combination, and the dose and schedule of ricolinostat recommended for further phase 2 investigation. Secondary outcomes were the pharmacokinetics and pharmacodynamics of ricolinostat in this combination and the preliminary anti-tumour activity of this treatment. The trial is closed to accrual and is registered at ClinicalTrials.gov, number NCT01583283.Findings: Between July 12, 2012, and Aug 20, 2015, we enrolled 38 patients. We observed two dose-limiting toxicities with ricolinostat 160 mg twice daily: one (2%) grade 3 syncope and one (2%) grade 3 myalgia event in different cohorts. A maximum tolerated dose was not reached. We chose ricolinostat 160 mg once daily on days 1-21 of a 28 day cycle as the recommended dose for future phase 2 studies in combination with lenalidomide 25 mg and dexamethasone 40 mg. The most common adverse events were fatigue (grade 1-2 in 14 [37%] patients; grade 3 in seven [18%]) and diarrhoea (grade 1-2 in 15 [39%] patients; grade 3 in two [5%]). Our pharmacodynamic studies showed that at clinically relevant doses, ricolinostat selectively inhibits HDAC6 while retaining a low and tolerable level of class I HDAC inhibition. The pharmacokinetics of ricolinostat and lenalidomide were not affected by co-administration. In a preliminary assessment of antitumour activity, 21 (55% [95% CI 38-71]) of 38 patients had an overall response.Interpretation: The findings from this study provide preliminary evidence that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma.Funding: Acetylon Pharmaceuticals. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
28. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
- Author
-
Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A. Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Jianping Wang, Khan, Imran, Ahmadi, Tahamtan, and Nahi, Hareth
- Subjects
- *
DRUG efficacy , *MULTIPLE myeloma treatment , *PROTEASOME inhibitors , *PROGRESSION-free survival , *IMMUNOSUPPRESSION , *ASPIRATION pneumonia - Abstract
The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. An updated pooled analysis of 148 patients treated with daratumumab 16 mg/kg is presented. Data were combined from part 2 of a "first-in-human," phase 1/2 study of patients who relapsed after or were refractory to ⩾2 prior therapies and a phase 2 study of patients previously treated with ⩾3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or were double refractory. Among the pooled population, patients received a median (range) of 5 (2-14) prior lines of therapy, and 86.5% were double refractory to a PI and IMID. Overall response rate was 31.1%, including 13 very good partial responses, 4 complete responses, and 3 stringent complete responses. The median duration of response was 7.6 months (95% confidence interval [CI], 5.6-not evaluable [NE]). The median progression-free survival (PFS) and overall survival (OS) was 4.0 months (95% CI, 2.8-5.6) and 20.1 months (95% CI, 16.6-NE), respectively. When stratified by responders versus stable disease/minimal response versus progressive disease/NE, median PFS was 15.0 months (95% CI, 7.4-NE) versus 3.0 months (95% CI, 2.8-3.7) versus 0.9 months (95% CI, 0.9-1.0), respectively, and median OS was NE (95% CI, NE-NE) versus 18.5 months (95% CI, 15.1-22.4) versus 3.7 months (95% CI, 1.7-7.6), respectively. No new safety signals were identified. In this pooled dataset, daratumumab 16 mg/kg monotherapy demonstrated rapid, deep, and durable responses, with a clinical benefit that extended to patients with stable disease or better. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
- Author
-
Nishijima, Tomohiro F., Shea, Thomas C., Wood, William A., Voorhees, Peter M., and Jamieson, Katarzyna
- Subjects
- *
LYMPHOBLASTIC leukemia treatment , *CANCER chemotherapy , *KIDNEY diseases , *COMA , *DNA synthesis , *DRUG approval - Abstract
The article focuses on a study regarding association of coma with use of nelarabine for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and chronic renal disease. Topics discussed include constitution of 9-b-arabinofuranosylguanine triphosphate (ara-GTP) in the drug that competes with deoxynucleosides in the cells causing inhibition of DNA synthesis, higher accumulation of ara-G in T-cells, and approval of the drug by the U.S. Food and Drug Administration in 2005.
- Published
- 2016
- Full Text
- View/download PDF
30. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
- Author
-
Hunsucker, Sally A., Magarotto, Valeria, Kuhn, Deborah J., Kornblau, Steven M., Wang, Michael, Weber, Donna M., Thomas, Sheeba K., Shah, Jatin J., Voorhees, Peter M., Xie, Hong, Cornfeld, Mark, Nemeth, Jeffrey A., and Orlowski, Robert Z.
- Subjects
- *
INTERLEUKIN-6 , *DRUG resistance , *MULTIPLE myeloma , *AMYLOIDOSIS , *APOPTOSIS , *PHOSPHORYLATION , *PHOSPHOINOSITIDES - Abstract
Signalling through the interleukin (IL)-6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether the IL-6-neutralizing monoclonal antibody siltuximab, formerly CNTO 328, could enhance the activity of melphalan, and to examine some of the mechanisms underlying this interaction. Siltuximab increased the cytotoxicity of melphalan in KAS-6/1, INA-6, ANBL-6, and RPMI 8226 human myeloma cell lines (HMCLs) in an additive-to-synergistic manner, and sensitized resistant RPMI 8226.LR5 cells to melphalan. These anti-proliferative effects were accompanied by enhanced activation of drug-specific apoptosis in HMCLs grown in suspension, and in HMCLs co-cultured with a human-derived stromal cell line. Siltuximab with melphalan enhanced activation of caspase-8, caspase-9, and the downstream effector caspase-3 compared with either of the single agents. This increased induction of cell death occurred in association with enhanced Bak activation. Neutralization of IL-6 also suppressed signalling through the phosphoinositide 3-kinase/Akt pathway, as evidenced by decreased phosphorylation of Akt, p70 S6 kinase and 4E-BP1. Importantly, the siltuximab/melphalan regimen demonstrated enhanced anti-proliferative effects against primary plasma cells derived from patients with myeloma, monoclonal gammopathy of undetermined significance, and amyloidosis. These studies provide a rationale for translation of siltuximab into the clinic in combination with melphalan-based therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
31. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
- Author
-
Fonseca, Rafael, Usmani, Saad Z, Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M, Nair, Sandhya, Potluri, Ravi, and Voorhees, Peter M
- Abstract
Background: For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities. Here, we examine frontline treatment patterns, and attrition rates by LOT among newly diagnosed MM (NDMM) patients in the United States who were eligible or ineligible for autologous stem cell transplant (ASCT).Methods: Data were identified from three US patient-level databases collectively covering the period January 2000 to September 2018. Patients had an index diagnosis of MM on or after January 1, 2007, medical and prescription insurance coverage at diagnosis, a 1-year look-back period prior to the index diagnosis, no prior malignancies in the 1-year period before index diagnosis, and had received ≥1 LOT.Results: Among patients who did not receive ASCT (non-transplant; n = 22,062), 12,557 (57%) received only 1 LOT and 9505 (43%) received > 1 LOT. Patients receiving only 1 LOT were significantly older, had higher mean Charlson Comorbidity Index (CCI) scores, and higher incidences of comorbidities. Among the 2763 patients receiving ASCT, 2184 received > 1 LOT, and 579 (21%) received only 1 LOT (ie, ASCT was the last treatment). 1682 (61%) patients received induction therapy as frontline treatment, of whom 187 (11%) also received consolidation therapy. The latter group was younger than those who received only induction therapy, had lower mean CCI scores, and comparable or lower incidences of selected comorbidities. The most common frontline therapy for non-transplant and transplant-eligible patients was bortezomib/dexamethasone and bortezomib/lenalidomide/dexamethasone, respectively. Attrition rates across all LOTs were high for non-transplant patients (range, 43-57%) and transplant patients (range, 21-37%). Treatment duration decreased by LOT for non-transplant patients and was consistent across LOTs for transplant patients.Conclusions: In this analysis, a substantial proportion of patients with NDMM who received frontline therapy did not appear to receive a subsequent LOT. These high attrition rates underscore the need to use the most optimal treatment regimens upfront rather than reserving them for later LOTs in which the clinical benefit may decrease. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.